Statistiche di base
| LEI | 549300SMWHEALCU7Q019 |
| CIK | 1385818 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aytu BioPharma, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 5, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2025 |
Exhibit 99.1 Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA™ Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million Expanded facilities allow for added working capi |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 20, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. AMENDMENT NO. 6 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 6 TO LOAN AND SECURITY AGREEMENT (this "Amendment") is dated as of June 20, 2025 (the "Amendment No. 6 Closing Da |
|
| June 17, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 17, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 17, 2025 |
Exhibit 99.1 |
|
| June 9, 2025 |
Exhibit 99.1 Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA™ Opportunity and Commercialization Plan Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu’s largest shareho |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 9, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 9, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-287728 and 333-287825 AYTU BIOPHARMA, INC. 1,366,668 shares of Common Stock and 8,233,332 Prefunded Warrants to Purchase 8,233,332 Shares of Common Stock and up to 8,233,332 Shares of Common Stock Underlying the Prefunded Warrants We are offering, on a firm commitment basis, 1,366,668 shares of common stock, par value $0.0001 |
|
| June 6, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 5, 2025 As filed with the U.S. Securities and Exchange Commission on June 5, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Stand |
|
| June 6, 2025 |
Exhibit 99.1 Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / June 6, 2025 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therape |
|
| June 6, 2025 |
Exhibit 1.1 1,366,668 Shares of Common Stock and 8,233,332 Pre-Funded Warrants to Purchase 8,233,332 Shares of Common Stock of AYTU BIOPHARMA, INC. UNDERWRITING AGREEMENT June 5, 2025 Lake Street Capital Markets, LLC As Representative of the several Underwriters 121 South 8th Street, Suite 1000 Minneapolis, MN 55402 Ladies and Gentlemen: 1. Introductory. Aytu BioPharma, Inc., a Delaware corporatio |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 5, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 5, 2025 Date of Report (Date of earliest event reported) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 6, 2025 |
Exhibit 99.1 Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA™ (gepirone) Extended-Release Tablets in the United States Aytu enters the over $22 billion United States prescription major depressive disorder (“MDD”) market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXX |
|
| June 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) AYTU BIOPHARMA, INC. |
|
| June 5, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 5, 2025 As filed with the U.S. Securities and Exchange Commission on June 5, 2025 Registration No. 333-287728 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organiza |
|
| June 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) AYTU BIOPHARMA, INC. |
|
| June 2, 2025 |
Exhibit 4.13 PREFUNDED COMMON STOCK PURCHASE WARRANT AYTU BIOPHARMA, INC. Warrant Shares: [•] Initial Exercise Date: [•], 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| June 2, 2025 |
June 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aytu BioPharma, Inc. Registration Statement on Form S-1 File No. 333-287728 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securitie |
|
| June 2, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 2, 2025 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 2, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2 |
|
| June 2, 2025 |
Form of Underwriting Agreement. Exhibit 1.1 [•] Shares of Common Stock and [•] Pre-Funded Warrants to Purchase [•] Shares of Common Stock of AYTU BIOPHARMA, INC. UNDERWRITING AGREEMENT [•], 2025 Lake Street Capital Markets, LLC As Representative of the several Underwriters 121 South 8th Street, Suite 1000 Minneapolis, MN 55402 Ladies and Gentlemen: 1. Introductory. Aytu BioPharma, Inc., a Delaware corporation (the “Company”), pr |
|
| June 2, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) AYTU BIOPHARMA, INC. |
|
| June 2, 2025 |
AYTU BIOPHARMA, INC. 7900 East Union Avenue, Suite 920 Denver, Colorado 80237 (720) 437-6580 AYTU BIOPHARMA, INC. 7900 East Union Avenue, Suite 920 Denver, Colorado 80237 (720) 437-6580 June 2, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aytu BioPharma, Inc.—Registration Statement on Form S-1 (File No. 333-287728) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 193 |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2025 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| May 21, 2025 |
Amendment to the Aytu BioPharma, Inc. 2023 Equity Incentive Plan. Exhibit 10.1 2023 EQUITY INCENTIVE PLAN AMENDMENT AMENDMENT TO THE AYTU BIOPHARMA, INC. 2023 EQUITY INCENTIVE PLAN Effective as of May 21, 2025 WHEREAS, the Board of Directors (the “Board”) of Aytu BioPharma, Inc. (the “Company”) heretofore established the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “Plan”); and WHEREAS, the Board desires to amend the Plan to increase the number of shares |
|
| May 14, 2025 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively Adjusted EBITDA1 of $3.9 million Total net revenue of $18.5 million up 32% year-over-year Company to host conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time DENVER, CO / May 14, 20 |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38247 AYTU BIOPHARMA, INC. |
|
| April 28, 2025 |
Table of Contents Confidential Treatment Requested By Aytu BioPharma, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on April 28, 2025 This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNIT |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| February 12, 2025 |
Exhibit 10.2 SEPARATION & RELEASE AGREEMENT This Separation & Release Agreement (“Separation Agreement” or “Agreement”) is entered into by and between Mark K. Oki (“you”) and Aytu BioPharma, Inc., and its predecessors, successors, assigns, parents, affiliates, subsidiaries, and related companies (collectively “the Company”). WHEREAS, your employment with the Company will terminate effective as of |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 12, 2025 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38247 AYTU BIOPHARMA, I |
|
| February 12, 2025 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call an |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 3, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| December 4, 2024 |
Exhibit 99.1 NOTICE OF PENDENCY OF DERIVATIVE ACTION, PROPOSED AGREEMENT OF SETTLEMENT AND RELEASE, AND SETTLEMENT HEARING TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. (“AYTU” OR THE “COMPANY”) AS OF OCTOBER 9, 2024 (THE “RECORD DATE”) (“CURRENT AYTU SHAREHOLDERS”). PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPO |
|
| November 13, 2024 |
AYTU / Aytu BioPharma, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 aytu13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aytu BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 054754858 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 11, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38247 AYTU BIOPHARMA, |
|
| November 13, 2024 |
Exhibit 10.1 AMENDED AND RE-STATED EMPLOYMENT AGREEMENT This Amended and Re-stated Employment Agreement (the "Agreement"), is effective as of November 11, 2024 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 7900 East Union Avenue, Suite 920, Denver, CO 80237 USA, (hereinafter referred to as the "Company"), and Ryan J. Selhorn (“Executive"). RECITALS W |
|
| November 13, 2024 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating optimization plan implemented to further streamline oper |
|
| October 11, 2024 |
As filed with the Securities and Exchange Commission on October 11, 2024 As filed with the Securities and Exchange Commission on October 11, 2024 Registration No. |
|
| October 7, 2024 |
Aytu BioPharma, Inc. 7900 East Union Avenue, Suite 920 Denver, CO 80237 Aytu BioPharma, Inc. 7900 East Union Avenue, Suite 920 Denver, CO 80237 October 7, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Aytu BioPharma, Inc. – Registration Statement on Form S-3 (File No. 333-282347) Ladies and Gentlemen: In accordance with Rule 460 and 461 under the |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 1, 2024 |
Exhibit 99.1 Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT® and Cotempla XR-ODT® in Canada Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / October 1, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (N |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in i |
|
| September 26, 2024 |
Certificate of Amendment to the Restated Certificate of Incorporation, effective May 20, 2020. Exhibit 3.6 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “AYTU BIOSCIENCE, INC.”, FILED IN THIS OFFICE ON THE TWENTIETH DAY OF MAY, A.D. 2020, AT 7:11 O`CLOCK P.M. 5759344 8100 SR# 20204290183 Authentication: 202974745 Date: 05-21-20 You may verify thi |
|
| September 26, 2024 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2 |
|
| September 26, 2024 |
Executive Compensation Clawback Policy. Exhibit 97.1 AYTU BIOPHARMA, INC. CLAWBACK POLICY EFFECTIVE December 1, 2023 1. Purpose. The purpose of this Aytu BioPharma Inc. (the “Company”) Clawback Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation from Covered Executive Officers in the event that the Company is required to prepare an Accounting Restatement. This Policy is designed to comply with, an |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| September 26, 2024 |
Exhibit 21.1 SUBSIDIARIES OF AYTU BIOPHARMA, INC. Name of Subsidiary State Jurisdiction 1. Aytu Therapeutics LLC Delaware 2. Cherry Creek Therapeutics, Inc. Delaware 3. Neos Therapeutics, Inc. Delaware 4. Neos Therapeutics Brands, LLC Delaware 5. Neos Therapeutics, LP Texas 6. PharmaFab Texas, LLC Texas 7. Innovus Pharmaceuticals, Inc. (1) Nevada 8. Delta Prime Savings Club, Inc. (1) Nevada 9. Sem |
|
| September 26, 2024 |
Exhibit 10.42 AMENDED AND RE-STATED EMPLOYMENT AGREEMENT This Amended and Re-Stated Employment Agreement (the “Agreement”), is effective as of March 20, 2023 (the “Effective Date”), between Aytu BioScience, Inc. (the “Company”), a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, Colorado, 80112, and Jarrett T. Disbrow (the “Employee”). RECITALS WHEREAS, the Compan |
|
| September 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) AYTU BIOPHARMA, INC. |
|
| September 26, 2024 |
Statement of Insider Trading Policy. Exhibit 19.1 |
|
| September 26, 2024 |
As filed with the Securities and Exchange Commission on September 26, 2024 As filed with the Securities and Exchange Commission on September 26, 2024 Registration No. |
|
| August 6, 2024 |
Exhibit 99.1 Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for Receipt of Future Sales-Based Royalty Payments DENVER, CO / August 6, 2024 / Ayt |
|
| August 6, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 26, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 18, 2024 |
Exhibit 99.1 Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan Term loan matur |
|
| June 18, 2024 |
AYTU / Aytu BioPharma, Inc. / Nantahala Capital Management, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2417545d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 2) (Rule 13d-101) Under the Securities Exchange Act of 1934 AYTU BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 054754858 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (N |
|
| June 18, 2024 |
Second Amended and Restated Revolving Note dated June 12, 2024. Exhibit 10.3 SECOND AMENDED AND RESTATED REVOLVING NOTE $14,500,000.00 June 12, 2024 The undersigned (each, a "Borrower" and collectively, the "Borrowers"), for value received, promises to pay to the order of ECLIPSE BUSINESS CAPITAL SPV, LLC (f/k/a ENCINA BUSINESS CREDIT SPV, LLC) ("Lender"), at its principal office, the aggregate unpaid amount of all Revolving Loans made to Borrowers by Lender p |
|
| June 18, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. CONSENT, JOINDER AND AMENDMENT NO. 5 TO LOAN AND SECURITY AGREEMENT This CONSENT, JOINDER AND AMENDMENT NO. 5 TO LOAN AND SECURITY AGREEMENT (this "Amendment") is dated as of June |
|
| June 18, 2024 |
Term Loan Note dated June 12, 2024. Exhibit 10.2 TERM LOAN NOTE $13,000,000.00 June 12, 2024 The undersigned (each, a "Borrower" and collectively, the "Borrowers"), for value received, promises to pay to the order of ECLIPSE BUSINESS CAPITAL SPV, LLC (f/k/a ENCINA BUSINESS CREDIT SPV, LLC) ("Lender"), at its principal office, the aggregate unpaid amount of the Term Loan made to Borrowers by Lender pursuant to the Loan Agreement (def |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU BIOPHARMA, INC. (Ex |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2024 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of p |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e) |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU BIOPHARMA, INC. |
|
| February 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2024 Date of Report (Date of earliest event reported): AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. COMMERCIAL MANUFACTURING SERVICES AGREEMENT This Commercial Manufacturing Services Agreement (this “Agreement”) is effective as of November 13, 2023 (the “Effective Date”) by and |
|
| February 14, 2024 |
Exhibit 99.1 Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023 $19 |
|
| February 13, 2024 |
AYTU / Aytu BioPharma, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 aytu13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aytu BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 054754858 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2023 |
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash balance at September 30, 2023 Company to host conference call today at 4:30pm ET DENVER, CO / November 14, 2023 / Aytu Bio |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AY |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| October 26, 2023 |
Exhibit 99.1 Aytu BioPharma Announces Approval of the Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product M |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38247 AYTU BIOPHARMA, INC. (Exact Name of Registrant |
|
| October 12, 2023 |
Exhibit 10.46 AMENDED AND RE-STATED EMPLOYMENT AGREEMENT This Amended and Re-stated Employment Agreement (the "Agreement"), is effective as of February 13, 2023 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Mark Oki (“Executive"). RECITALS WHEREA |
|
| October 12, 2023 |
Exhibit 10.50 INTERIM AMENDMENT TO LEASE This INTERIM AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of September 4, 2003, by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (hereinafter referred to as “Landlord”), and PFAB LP, a Texas limited partnership (hereinafter referred to as “Tenant”). BACKGROUND: A. Walstib, L.P. (“Walstib”) and |
|
| October 12, 2023 |
Fifth Amendment to Lease dated April 5, 2010, between TIAA and Neos Therapeutics, LP. Exhibit 10.53 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this Amendment) is made and entered into as of April ., 2010 (the Execution Date), by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (Landlord), and NEOS THERAPEUTICS, LP, a Texas limited partnership, formerly known as PFAB LP (Tenant). BACKGROUND: A. Walstib, L.P., a Delaware limited p |
|
| October 12, 2023 |
First Amendment to Lease dated September 1, 2002, between Walstib, L.P. and PFAB, LP. Exhibit 10.49 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “Amendment”) is made to be effective as of September 1, 2002, by and between WALSTIB, L.P., a Delaware limited partnership (“Landlord”), and PFAB, LP, a Texas limited partnership (“Tenant”). RECITALS A.Landlord and PharmaFab, Inc., a Texas corporation (“PharmaFab”), entered into that certain Commercial Lease Agreement dated |
|
| October 12, 2023 |
Third Amendment to Lease dated October 1, 2003, Between TIAA and PFAB, LP. Exhibit 10.51 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of , 2003, by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (hereinafter referred to as “Landlord”), and PFAB LP, a Texas limited partnership (hereinafter referred to as “Tenant”). BACKGROUND: A. Walstib, L.P. (“Walstib”) and PharmaFab, Inc |
|
| October 12, 2023 |
Exhibit 10.52 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this Amendment) is made and entered into as of June , 2009 (the Execution Date), to be effective as of May 1, 2009 (the Effective Date), by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, a New York corporation (Landlord), and NEOS THERAPEUTICS, LP, a Texas limited partnership, formerly known as PFAB LP (Ten |
|
| October 12, 2023 |
Commercial Lease Agreement dated June 10, 1999, between Walstib, L.P. and Pharmafab, Inc. Exhibit 10.48 TRAMMELL CROW COMPANY COMMERCIAL LEASE AGREEMENT WALSTIB, L.P., A DELAWARE LIMITED PARTNERSHIP Landlord AND PHARMAFAB, INC. Tenant TABLE OF CONTENTS Page 1. BASIC PROVISIONS 1 1.1.Parties 1 1.2.Premises 1 1.3.Term 1 1.4.Base Rent 1 1.5.Tenant’s Share of Operating Expenses 1 1.6.Tenant’s Estimated Monthly Rent Payment 1 1.7.Security Deposit 2 1.8.Permitted Use 2 1.9.Guarantor 2 1.10.A |
|
| October 12, 2023 |
Exhibit 10.45 AMENDED AND RE-STATED EMPLOYMENT AGREEMENT This Amended and Re-Stated Employment Agreement (the "Agreement"), is effective as of February 13, 2023 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Joshua R. Disbrow (“Employee"). RECITAL |
|
| October 12, 2023 |
Exhibit 10.55 AMENDED AND RE-STATED EMPLOYMENT AGREEMENT This Amended and Re-Stated Employment Agreement (the "Agreement"), is effective as of March 21, 2023 (the "Effective Date"), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Greg Pyszczymuka as ("Executive"). RECITAL |
|
| October 12, 2023 |
Exhibit 10.47 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of May 15, 2023, and is made by and between Neos Therapeutics, LP, a Texas limited partnership (“Sublessor”), and AMT Manufacturing Solutions, LLC, a Delaware limited liability company (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1.Recitals: This Sublease is made with reference to the fact |
|
| October 12, 2023 |
Exhibit 10.54 SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease (“Amendment”) is made effective as of August , 2013, by and between RIVERSIDE BUSINESS GREEN, LP, a Delaware limited partnership (“Landlord”) and NEOS THERAPEUTICS, LP, a Texas limited partnership (“Tenant”), with reference to the following facts and circumstances. A. Landlord is the owner of that certain building located at 2940 |
|
| October 12, 2023 |
Exhibit 21.1 SUBSIDIARIES OF AYTU BIOPHARMA, INC. Name of Subsidiary State Jurisdiction 1. Aytu Therapeutics, LLC Delaware 2. Innovus Pharmaceuticals, Inc. Nevada 3. Semprae Laboratories, Inc Delaware 4. Supplement Hunt, Inc. Nevada 5. Delta Prime Savings Club, Inc Nevada 6. Neos Therapeutics, Inc. Delaware 7. Neos Therapeutics Brands, LLC Delaware 8. Neos Therapeutics, LP Texas 9. PharmaFab Texas |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-38247 (Check one): ⌧ Form 10-K ◻ Form 20-F ◻ Form 11-K ◻ Form 10-Q ◻ Form 10-D ◻ Form N-SAR ◻ Form N-CSR For Period Ended: June 30, 2023 ◻ Transition Report on Form 10-K ◻ Transition Report on Form 20-F ◻ Transition Report on Form 11-K ◻ Transition Report on Fo |
|
| September 27, 2023 |
Exhibit 99.1 Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023 Company t |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2023 |
Exhibit 99.1 Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT® and Cotempla XR-ODT® in Israel and the Palestinian Authority After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHD ENGLEWOOD, CO and GIVATAYIM, ISRAEL/ Jul |
|
| July 10, 2023 |
Exhibit 99.1 Aytu BioPharma Announces Submission of Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotemp |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Aytu BioPharma, Inc. |
|
| June 23, 2023 |
Aytu BioPharma, Inc. 2023 Equity Incentive Plan. Exhibit 10.1 AYTU BIOPHARMA, INC. 2023 Equity INCENTIVE PLAN Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its stockholders by aiding the Company in attracting and retaining employees, officers, consultants, advisors and non-employee Directors capable of assuring the future success of the Company, to offer such persons incentives to put forth maximum eff |
|
| June 23, 2023 |
As filed with the Securities and Exchange Commission on June 23, 2023 As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. |
|
| June 16, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 1) (Rule 13d-101) Under the Securities Exchange Act of 1934 AYTU BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 054754858 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (Name, Address and Telephone Number of Perso |
|
| June 16, 2023 |
US0547548588 / Aytu BioPharma, Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aytu BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 054754858 (CUSIP Number) June 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| June 12, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-271556 1,743,695 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 430,217 Shares of Common Stock, Tranche A Warrants to Purchase Up to 2,173,912 Shares of Common Stock Tranche B Warrants to Purchase up to 2,173,912 Shares of Common Stock, and Up to 4,347,824 Shares of Common Stock Underlying the Common Warrants a |
|
| June 12, 2023 |
Exhibit 99.1 Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director Abhinav Jain of Nantahala Capital Management, LLC Joins the Company’s Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term Loan Through January 2025 |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2023 |
Filed Pursuant to Rule 433 Free Writing Prospectus dated June 9, 2023 Relating to Preliminary Prospectus dated June 5, 2023 Registration No. |
|
| June 7, 2023 |
Aytu Biopharma, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Aytu Biopharma, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 June 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jason L. Drory Re: Aytu Biopharma, Inc. – Registration Statement on Form S-1 (File No. 333-271556) Ladies and Gentlemen: In accordance with Rule 461 under the Sec |
|
| June 7, 2023 |
June 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Aytu Biopharma, Inc. Registration Statement on Form S-1, as amended File No. 333-271556 Ladies and Gentlemen: As the placement agent of the proposed offering of Aytu Biopharma, Inc. (the “Company”), we hereby join the Company’s request for acceleration o |
|
| June 6, 2023 |
Filed Pursuant to Rule 433 Free Writing Prospectus dated June 6, 2023 Relating to Preliminary Prospectus dated June 5, 2023 Registration No. |
|
| June 5, 2023 |
Form of Placement Agency Agreement. Exhibit 10.42 PLACEMENT AGENCY AGREEMENT , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Aytu Biopharma, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the "Common Sto |
|
| June 5, 2023 |
Exhibit 4.10 FORM OF PREFUNDED COMMON STOCK PURCHASE WARRANT AYTU BIOPHARMA, INC. Warrant Shares: [XX] Initial Exercise Date: [XX] THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [PURCHASER] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 5, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 5, 2023 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on June 5, 2023 Registration No. 333-271556 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pre-effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aytu Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-0883144 (State or |
|
| June 5, 2023 |
Exhibit 4.11 [FORM OF TRANCHE A WARRANT] AYTU BIOPHARMA, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS Warrant No.: Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”) Date of Issuance: [], 2023 (“Issuance Date”) Aytu BioPharma, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the |
|
| June 5, 2023 |
Exhibit 4.12 [FORM OF TRANCHE B WARRANT] AYTU BIOPHARMA, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS Warrant No.: Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”) Date of Issuance: [], 2023 (“Issuance Date”) Aytu BioPharma, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the |
|
| June 5, 2023 |
Form of Securities Purchase Agreement. Exhibit 10.43 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Aytu Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| May 26, 2023 |
US0547548588 / Aytu BioPharma, Inc. / Nantahala Capital Management, LLC - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No.) (Rule 13d-101) Under the Securities Exchange Act of 1934 AYTU BIOPHARMA, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 054754858 (CUSIP NUMBER) Taki Vasilakis 130 Main St. 2nd Floor New Canaan, CT 06840 (203) 308-4440 (Name, Address and Telephone Number of Person |
|
| May 26, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock, par value $0.0001 per share, of Aytu BioPharma Inc. and further agree to the filing of this agreement as an Exhibit thereto |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYTU B |
|
| May 11, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO LOAN DOCUMENTS This Second Amendment to Loan Documents (this “Amendment”) is entered into as of March 24, 2023, by and among AVENUE CAPITAL MANAGEMENT II L.P., a Delaware limited partnership, as administrative and collateral agent (in such capacity, “Agent”), the other Lenders party hereto and AYTU BIOPHARMA, INC., a Delaware corporation (together with each other p |
|
| May 11, 2023 |
Exhibit 10.1 AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 4 TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of March 24, 2023 (the “Amendment No. 4 Closing Date”) by and among NEOS THERAPEUTICS, INC., a Delaware corporation (“Company”), NEOS THERAPEUTICS BRANDS, LLC, a Delaware limited liability company (“NT Brands”), NEOS THERAPEUTICS, LP, a Texas limited partne |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SETTLEMENT AND TERMINATION OF LICENSE AGREEMENT This Settlement and Termination of License Agreement (the “Settlement Agreement”) is made as of May 12, 2022 (the “Settlement Effective Date”), by and between Aytu Bio |
|
| May 11, 2023 |
Exhibit 99.1 Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results Total prescriptions increased 32% compared to Q3 2022 to highest level in Company history Company to host conference call today at 4:30pm ET ENGLEWOOD, CO / May 11, 2023 / / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pedia |
|
| May 1, 2023 |
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility Exhibit 99.1 Aytu BioPharma Subleases a Portion of Its Manufacturing Facility ENGLEWOOD, CO / May 1, 2023 / Aytu BioPharma, Inc. (the “Company” or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC (“AMTMS”), |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Aytu Biopharma, Inc. |
|
| May 1, 2023 |
As filed with the U.S. Securities and Exchange Commission on May 1, 2023 TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on May 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aytu Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 47-0883144 (State or other jurisdiction of incorporati |
|
| April 27, 2023 |
EX-99.1 2 aytu-20230427xex99d1.htm EX-99.1 Exhibit 99.1 Aytu BioPharma Announces Approval of Adzenys XR-ODT® Manufacturing Site Transfer U.S. Food & Drug Administration Approval of Prior Approval Supplement Enables Transfer of Adzenys Production to Contract Manufacturer in 2023 Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Improve ADHD Product |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| April 7, 2023 |
our definitive proxy statement on Schedule 14A, filed with the SEC on April 7, 2023; and UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| February 21, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil |
|
| February 21, 2023 |
Exhibit 99.1 Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00 pm ET ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer heal |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| February 21, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AYT |
|
| February 15, 2023 |
NT 10-Q 1 tm236983d1nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 001-38247 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Rep |
|
| February 14, 2023 |
AYTU / Aytu BioScience, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm235037d22sc13ga.htm SC 13G/A CUSIP No: 054754858 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Aytu BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Cl |
|
| February 14, 2023 |
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results Exhibit 99.1 Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results ENGLEWOOD, CO / February 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the delayed filing of its Form 10 |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| January 25, 2023 |
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance Exhibit 99.1 Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance ENGLEWOOD, CO / January 25, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that it received a written notification from the Listing Qual |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| January 5, 2023 |
Certificate of Amendment of Certificate of Incorporation, effective January 4, 2023. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF AYTU BIOPHARMA, INC. Aytu BioPharma, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: FIRST: The name of the corporation is Aytu BioPharma, Inc. and that this corporation was originally |
|
| January 5, 2023 |
Aytu BioPharma Announces 1-for-20 Reverse Stock Split Exhibit 99.1 Aytu BioPharma Announces 1-for-20 Reverse Stock Split ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, eff |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2022 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ? ? ? ? nd ? ? ? ? RAFAL APONOWICZ, derivatively on behalf of Aytu Biopharma, Inc. and individually on behalf of himself and all other similarly situated stockholders of Aytu Biopharma, Inc., Plaintiff, v. GARY CANTRELL, JOSHUA DISBROW, CARL DOCKERY, JOHN DONOFRIO, JR., AND MICHAEL MACALUSO, Defendants, and AYTU BIOPHARMA, INC., Nomina |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2022 |
Letter from Plante & Moran PLLC, dated December 12, 2022 Exhibit 16.1 December 12, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K of Aytu BioPharma, Inc. dated December 12, 2022, and agree with the statements concerning our firm contained therein. We have no basis to agree or disagree with other statements of the registrant contained therein. Very truly yours, Plante & Mo |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 30, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT® Prescriptions Generated Since Inception of RxConnect Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the Adderall® XR Supply Disruption Adzenys XR-ODT is the Only FDA-Approved, Exten |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 22, 2022 |
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule Exhibit 99.1 Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule ENGLEWOOD, CO / November 22, 2022 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the Company recei |
|
| November 16, 2022 |
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso EX-99 2 aytu-20221116xex99.htm EX-99 Exhibit 99.1 Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso ENGLEWOOD, CO / November 16, 2022 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-239010 AMENDMENT NO. 1 DATED NOVEMBER 14, 2022 to Prospectus Supplement dated June 4, 2021 (to Prospectus dated June 17, 2020) Up to $4,300,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this "Amendment") amends our prospectus supplement dated June 4, 2021 (the "Prospectus Supplement"). We previously entered into a Controlled E |
|
| November 14, 2022 |
EX-99 2 aytu-20221114xex99.htm EX-99 Exhibit 99.1 Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment Positive Adjusted EBITDA for the Quarter of $1.4 Million Leadership Changes Implemented to Focus on Commercial Operations Company to Host Conference Call T |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38247 AY |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| November 7, 2022 |
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 Exhibit 99.1 Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 ENGLEWOOD, CO / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its first qu |
|
| October 25, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company’s Term Loan Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Over $3 Million in Principal Payments Beyond 2023 Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement o |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission F |
|
| October 13, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and near-term cash flow generation Aytu is expecting to |
|
| October 6, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (C |
|
| October 5, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT® in Response to Reported Generic Adderall® XR Supply Disruptions Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR Reported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD Medications ENGLEWOOD, CO / October 5, 2022 / Aytu BioPharma, |
|
| October 5, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (C |
|
| September 28, 2022 |
? ? Exhibit 99.1 ? ? Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue ? Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segment ? Positive Adjusted EBITDA within Prescription segment ? Company to Host Conference Call Today at 4:30pm ET ? ENGLEWOOD, CO / September 27, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical comp |
|
| September 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? |
|
| September 27, 2022 |
Exhibit 4.9 ? DESCRIPTION OF SECURITIES ? General ? This describes the general terms of our capital stock. For a more detailed description of our capital stock, you should read the applicable provisions of the Delaware General Corporation Law, or DGCL, and our charter and bylaws. Our certificate of incorporation provides that we may issue up to 200,000,000 shares of common stock, par value $0.0001 |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 27, 2022 |
Exhibit 21.1 ? SUBSIDIARIES OF AYTU BIOPHARMA, INC. ? ? ? ? ? ? ? Name of Subsidiary State Jurisdiction ? ? ? 1. Aytu Therapeutics, LLC Delaware 2. Innovus Pharmaceuticals, Inc. Nevada 3. Semprae Laboratories, Inc Delaware 4. Supplement Hunt, Inc. Nevada 5. Delta Prime Savings Club, Inc Nevada 6. Neos Therapeutics, Inc. Delaware 7. Neos Therapeutics Brands, LLC Delaware 8. Neos Therapeutics, LP Te |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant?? Filed by a Party other than the Registrant?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| September 21, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? SCHEDULE 14A ? (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? ? Definitive Proxy Statement ? ? ? Definitive Additional Materials ? ? ? Soliciting Material Pursuant to ? 240. |
|
| September 20, 2022 |
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 ? ? Exhibit 99.1 ? Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 ? ENGLEWOOD, CO / September 20, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, will report financial results for its fourth quarter and fiscal y |
|
| September 20, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? |
|
| September 14, 2022 |
Exhibit 99.1 ? ? ? Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin ? This Fourth Patent for AR101/Enzastaurin Strengthens and Broadens the Intellectual Property Portfolio Surrounding the Treatment of Inherited Vascular Disorders Including Vascular Ehlers-Danlos Syndrome (VEDS). ? Multiple Patent Families Filed in Key Global Markets ? ENGLEWOOD, CO / September 14, 2 |
|
| September 14, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? |
|
| August 25, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A ? (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| August 16, 2022 |
Exhibit 99.1 ? ? Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin ? First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome ? Multiple Patent Families Filed in Key Global Markets ? ENGLEWOOD, CO / August 16, 2022 / Aytu BioPharma, Inc. (the ?Company? or ?Aytu?) (Nasdaq |
|
| August 16, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (C |
|
| August 15, 2022 |
AYTU / Aytu BioScience, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: ?????054754874 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* Aytu BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 054754874 (CUSIP Nu |
|
| August 15, 2022 |
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering Exhibit 99.1 Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering of (i) 21,505,814 shares of i |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| August 15, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2022 |
Aytu BioPharma Announces Pricing of Public Offering Exhibit 99.2 Aytu BioPharma Announces Pricing of Public Offering ENGLEWOOD, CO, August 9, 2022 - Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain inv |
|
| August 10, 2022 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT aytu biopharma, inc. Warrant Shares: ????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????Initial Exercise Date: [?], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon t |
|
| August 10, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-259862? PROSPECTUS SUPPLEMENT (to Prospectus dated October 7, 2021) 21,505,814 Shares of Common Stock Pre-funded Warrants to Purchase 1,750,000 Shares of Common Stock Warrants to Purchase 23,255,814 Shares of Common Stock Aytu BioPharma, Inc. We are offering (i) 21,505,814 shares of our common stock, $0.0001 par value per s |
|
| August 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 (August 8, 2022) AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporatio |
|
| August 10, 2022 |
Underwriting Agreement dated August 9, 2022 EX-1.1 2 tm2222304d3ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution AYTU BIOPHARMA, INC. (a Delaware corporation) 21,505,814 Shares of Common Stock Pre-Funded Warrants to Purchase 1,750,000 Shares of Common Stock Warrants to Purchase 23,255,814 Shares of Common Stock UNDERWRITING AGREEMENT August 9, 2022 Cantor Fitzgerald & Co. Canaccord Genuity LLC As Representatives of the several Underwriters liste |
|
| August 10, 2022 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT AYTU BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: [?], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| August 10, 2022 |
Aytu BioPharma Announces Launch of Public Offering Exhibit 99.1 Aytu BioPharma Announces Launch of Public Offering ENGLEWOOD, CO, August 8, 2022 - Aytu BioPharma, Inc. (the ?Company? or ?Aytu?) (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choos |
|
| August 8, 2022 |
SUBJECT TO COMPLETION, DATED AUGUST 8, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 20, 2022 |
Exhibit 99.1 ? Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO / July 20, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for Vascula |
|
| July 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Com |
|
| July 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Com |
|
| July 1, 2022 |
Form of Indemnification Agreement. Exhibit 10.1 Form of Indemnification Agreement INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of by and between Aytu BioPharma, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in order to in |
|
| June 29, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Com |
|
| June 29, 2022 |
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company’s Board of Directors Exhibit 99.1 Aytu BioPharma Announces the Appointment of Vivian Liu to the Company’s Board of Directors ENGLEWOOD, CO / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company’s board of directors, effective July 1, 2022. Ms. Liu will serve as an independ |
|
| June 16, 2022 |
June 16, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| June 8, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on June 8, 2022 Registration No. |
|
| June 8, 2022 |
EX-FILING FEES 4 tmb-20220608xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) AYTU BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri |
|
| May 27, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Comm |
|
| May 20, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Comm |
|
| May 16, 2022 |
Exhibit 99.1 ? Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and Performance and Preparing Pipeline for Long-term Value Creation Englewood, CO, May 16 |
|
| May 16, 2022 |
CONFIDENTIAL Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SETTLEMENT AND TERMINATION OF LICENSE AGREEMENT This Settlement and Termination of License Agreement (the ?Settlement Agreement?) is made as of May 12, 2022 (the ?Settlement Effective Date?), by and bet |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): ? May 16, 2022 ? AYTU BIOPHARMA, INC. ? (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorpor |
|
| May 16, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 9, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Commi |
|
| May 9, 2022 |
? Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF AYTU BIOPHARMA, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may |
|
| April 25, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight? Delivery Technology Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO ? April 25, 2022 ? Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused |
|
| April 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 19, 2022 |
Exhibit 99.1 Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome ENGLEWOOD, CO / April 19, 2022 / Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AR101 (en |
|
| April 19, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Co |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to ? 240. |
|
| April 7, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy Statement ? ? Definitive Additional Materials ? ? Soliciting Material Pursuant to ? 240. |
|
| March 23, 2022 |
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT® Exhibit 99.1 ? ? Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT? ? ENGLEWOOD, CO / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued US patent No. 11,166,947 for Cotempla XR-ODT? (methylphenidate) extended-release orally disin |
|
| March 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Co |
|
| March 4, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Com |
|
| March 4, 2022 |
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering Exhibit 99.1 Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering ENGLEWOOD, CO, March 2, 2022 – Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to a healthcare-dedicated institutional investor in an underwritten offering of 3,030,000 shares of its common stock, pre-funded warr |
|
| March 4, 2022 |
Exhibit 1.1 AYTU BIOPHARMA, INC. (a Delaware corporation) 3,030,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,030,000 Shares of Common Stock Warrants to Purchase 6,666,000 Shares of Common Stock UNDERWRITING AGREEMENT ? ? March 2, 2022 ? ? Canaccord Genuity LLC 535 Madison Avenue, 2nd Floor New York, NY 10022 ? ? Ladies and Gentlemen: ? Aytu BioPharma, Inc., a Delaware corporation ( |
|
| March 4, 2022 |
Form of Prefunded Common Stock Purchase Warrant. Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT AYTU BIOPHARMA, INC. ? Warrant Shares: Issue Date: March, 2022 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Original Issue Da |
|
| March 4, 2022 |
Form of Common Stock Purchase Warrant. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT AYTU BIOPHARMA, INC. Warrant Shares: Issue Date: March, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 7, 2022 (the ?Initial Exercise Da |
|
| March 4, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-259862 PROSPECTUS SUPPLEMENT (to Prospectus dated October 7, 2021) ? 3,030,000 Shares of Common Stock Prefunded Warrants to Purchase 3,030,000 Shares of Common Stock Warrants to Purchase 6,666,000 Shares of Common Stock Aytu BioPharma, Inc. We are offering (i) 3,030,000 shares of our common stock, $0.0001 par value per share, |
|
| March 3, 2022 |
SUBJECT TO COMPLETION, DATED MARCH 2, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259862 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| March 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-38247 47-0883144 (State or other jurisdiction of incorporation) ? (Com |
|
| March 2, 2022 |
Exhibit 99.1 ? ? Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome ? ENGLEWOOD, CO, March 2, 2022 ? Aytu BioPharma, Inc. (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European Commission granted orphan designation to AR101 (enzastaurin), a PKC? inhibitor, |
|
| February 22, 2022 |
? February 22, 2022 ? VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N. |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 10-K/A ? ? ? ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the fiscal year ended June 30, 2021 ? OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Commission File Number 001-38247 AYTU BIOPHARMA, INC. (Exact Name of |
|
| February 14, 2022 |
? February 14, 2022 ? VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N. |
|
| February 14, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 14, 2022 |
Exhibit 10.2 RESTRICTED STOCK AWARD AGREEMENT This RESTRICTED STOCK AWARD AGREEMENT (the ?Agreement?) is made and entered into as of January 17, 2022, (the ?Grant Date?), by and between Aytu BioPharma, Inc., a Delaware corporation (the ?Company?), and Mark Oki (the ?Grantee?). WHEREAS, in order to induce the Grantee to be employed as Chief Financial Officer of the Company, the Company?s Compensati |
|
| February 14, 2022 |
Exhibit 10.3 ?INFORMATION IN THIS EXHIBIT IDENTIFIED BY THE MARK ?[INTENTIONALLY OMITTED]? IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED? LOAN AND SECURITY AGREEMENT Dated as of January 26, 2022 among Aytu BioPharma, Inc., a Delaware corporat |
|
| February 14, 2022 |
Registration Rights Agreement dated January 26, 2022 between Aytu and each of the warrant holders. Exhibit 10.5 ? REGISTRATION RIGHTS AGREEMENT ? This Registration Rights Agreement (this ?Agreement?) is made and entered into as of January 26, 2022, between Aytu BioPharma, Inc., a Delaware corporation (the ?Company?), and each of the several warrant holders signatory hereto (each such warrant holder, a ?Warrant Holder? and, collectively, the ?Warrant Holders?). ? This Agreement is made pursuant |
|
| February 14, 2022 |
Exhibit 10.4 ?INFORMATION IN THIS EXHIBIT IDENTIFIED BY THE MARK ?[INTENTIONALLY OMITTED]? IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.? ? CONSENT, JOINDER AND AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT This CONSENT, JOINDER AND AMENDME |
|
| February 14, 2022 |
EX-99.1 2 aytu-20220214xex99d1.htm EX-99.1 Exhibit 99.1 Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized, Sham-controlled Study of Healight in Patients w |
